Judith N Kloth

Summary

Affiliation: Leiden University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines
    Judith N Kloth
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Carcinogenesis 26:1493-502. 2005
  2. pmc Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer
    Judith N Kloth
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Genomics 8:53. 2007
  3. ncbi request reprint Lack of TNFalpha mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation
    Judith N Kloth
    Department of Pathology, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    Mol Immunol 45:152-9. 2008
  4. doi request reprint Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival
    Judith N Kloth
    Department of Pathology, The Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 21:866-75. 2008
  5. ncbi request reprint Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element
    Sytse J Piersma
    Department of Clinical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
    Int J Cancer 122:486-94. 2008

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines
    Judith N Kloth
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Carcinogenesis 26:1493-502. 2005
    ..TGF-beta1 excretion by tumor cells more likely contributes to paracrine stimulation of tumor development...
  2. pmc Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer
    Judith N Kloth
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Genomics 8:53. 2007
    ..Integration of these 3 platforms allows detection of genomic alterations at high resolution and investigation of an association between copy number changes and expression...
  3. ncbi request reprint Lack of TNFalpha mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation
    Judith N Kloth
    Department of Pathology, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    Mol Immunol 45:152-9. 2008
    ..In conclusion, TNFalpha mRNA expression is absent in nearly half of the cervical tumors analyzed. Neither promoter methylation nor genetic causes for lack of expression were evident...
  4. doi request reprint Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival
    Judith N Kloth
    Department of Pathology, The Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 21:866-75. 2008
    ..003 and P=0.003, respectively) and overall 5-year survival (P=0.003 and P=0.010, respectively). Our findings support the hypothesis that Smad4 is a target molecule for functional inactivation in cervical cancer...
  5. ncbi request reprint Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element
    Sytse J Piersma
    Department of Clinical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
    Int J Cancer 122:486-94. 2008
    ..This is crucial for the optimization of cancer immunotherapy in patients with pre-existing tumor-immunity...